CN115737478B - 沙漠藻护肤原料在制备皮肤舒缓剂中的应用 - Google Patents
沙漠藻护肤原料在制备皮肤舒缓剂中的应用 Download PDFInfo
- Publication number
- CN115737478B CN115737478B CN202310029859.4A CN202310029859A CN115737478B CN 115737478 B CN115737478 B CN 115737478B CN 202310029859 A CN202310029859 A CN 202310029859A CN 115737478 B CN115737478 B CN 115737478B
- Authority
- CN
- China
- Prior art keywords
- skin
- algae
- skin care
- raw material
- phase
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
- 241000195493 Cryptophyta Species 0.000 title claims abstract description 96
- 239000002994 raw material Substances 0.000 title claims abstract description 60
- 238000002360 preparation method Methods 0.000 title claims description 16
- 239000003795 chemical substances by application Substances 0.000 claims abstract description 45
- 150000003278 haem Chemical class 0.000 claims abstract description 35
- 102000009571 Macrophage Inflammatory Proteins Human genes 0.000 claims abstract description 14
- 108010009474 Macrophage Inflammatory Proteins Proteins 0.000 claims abstract description 14
- 239000000047 product Substances 0.000 claims description 42
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 25
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 claims description 21
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims description 20
- 239000000284 extract Substances 0.000 claims description 16
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 claims description 15
- CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 claims description 14
- 241000192701 Microcystis Species 0.000 claims description 14
- 239000000287 crude extract Substances 0.000 claims description 12
- 230000001804 emulsifying effect Effects 0.000 claims description 12
- 238000003756 stirring Methods 0.000 claims description 12
- 239000003921 oil Substances 0.000 claims description 11
- 235000019198 oils Nutrition 0.000 claims description 11
- 239000000843 powder Substances 0.000 claims description 11
- 239000006228 supernatant Substances 0.000 claims description 11
- POJWUDADGALRAB-UHFFFAOYSA-N allantoin Chemical compound NC(=O)NC1NC(=O)NC1=O POJWUDADGALRAB-UHFFFAOYSA-N 0.000 claims description 10
- 239000006071 cream Substances 0.000 claims description 10
- 150000004676 glycans Chemical class 0.000 claims description 10
- 238000000034 method Methods 0.000 claims description 10
- 229920001282 polysaccharide Polymers 0.000 claims description 10
- 239000005017 polysaccharide Substances 0.000 claims description 10
- KWIUHFFTVRNATP-UHFFFAOYSA-N Betaine Natural products C[N+](C)(C)CC([O-])=O KWIUHFFTVRNATP-UHFFFAOYSA-N 0.000 claims description 9
- 238000002386 leaching Methods 0.000 claims description 9
- 239000000049 pigment Substances 0.000 claims description 9
- 239000000126 substance Substances 0.000 claims description 9
- 238000001035 drying Methods 0.000 claims description 8
- 102000004169 proteins and genes Human genes 0.000 claims description 8
- 108090000623 proteins and genes Proteins 0.000 claims description 8
- OAABHEHWRQAHEJ-UHFFFAOYSA-N butan-1-ol;chloroform Chemical compound ClC(Cl)Cl.CCCCO OAABHEHWRQAHEJ-UHFFFAOYSA-N 0.000 claims description 7
- 229920001577 copolymer Polymers 0.000 claims description 7
- 238000000855 fermentation Methods 0.000 claims description 7
- 230000004151 fermentation Effects 0.000 claims description 7
- VBICKXHEKHSIBG-UHFFFAOYSA-N 1-monostearoylglycerol Chemical compound CCCCCCCCCCCCCCCCCC(=O)OCC(O)CO VBICKXHEKHSIBG-UHFFFAOYSA-N 0.000 claims description 6
- DWHIUNMOTRUVPG-UHFFFAOYSA-N 2-[2-[2-[2-[2-[2-(2-dodecoxyethoxy)ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethanol Chemical compound CCCCCCCCCCCCOCCOCCOCCOCCOCCOCCOCCO DWHIUNMOTRUVPG-UHFFFAOYSA-N 0.000 claims description 6
- NIXOWILDQLNWCW-UHFFFAOYSA-N Acrylic acid Chemical compound OC(=O)C=C NIXOWILDQLNWCW-UHFFFAOYSA-N 0.000 claims description 6
- HEDRZPFGACZZDS-UHFFFAOYSA-N Chloroform Chemical compound ClC(Cl)Cl HEDRZPFGACZZDS-UHFFFAOYSA-N 0.000 claims description 6
- SNPLKNRPJHDVJA-ZETCQYMHSA-N D-panthenol Chemical compound OCC(C)(C)[C@@H](O)C(=O)NCCCO SNPLKNRPJHDVJA-ZETCQYMHSA-N 0.000 claims description 6
- LRHPLDYGYMQRHN-UHFFFAOYSA-N N-Butanol Chemical compound CCCCO LRHPLDYGYMQRHN-UHFFFAOYSA-N 0.000 claims description 6
- 238000001816 cooling Methods 0.000 claims description 6
- 229940075529 glyceryl stearate Drugs 0.000 claims description 6
- 238000010438 heat treatment Methods 0.000 claims description 6
- 230000002401 inhibitory effect Effects 0.000 claims description 6
- 229940031674 laureth-7 Drugs 0.000 claims description 6
- 238000002156 mixing Methods 0.000 claims description 6
- 229940101267 panthenol Drugs 0.000 claims description 6
- 235000020957 pantothenol Nutrition 0.000 claims description 6
- 239000011619 pantothenol Substances 0.000 claims description 6
- 229940100460 peg-100 stearate Drugs 0.000 claims description 6
- 229920002401 polyacrylamide Polymers 0.000 claims description 6
- DNIAPMSPPWPWGF-VKHMYHEASA-N (+)-propylene glycol Chemical compound C[C@H](O)CO DNIAPMSPPWPWGF-VKHMYHEASA-N 0.000 claims description 5
- 229940015975 1,2-hexanediol Drugs 0.000 claims description 5
- YPFDHNVEDLHUCE-UHFFFAOYSA-N 1,3-propanediol Substances OCCCO YPFDHNVEDLHUCE-UHFFFAOYSA-N 0.000 claims description 5
- 229940035437 1,3-propanediol Drugs 0.000 claims description 5
- QCDWFXQBSFUVSP-UHFFFAOYSA-N 2-phenoxyethanol Chemical compound OCCOC1=CC=CC=C1 QCDWFXQBSFUVSP-UHFFFAOYSA-N 0.000 claims description 5
- POJWUDADGALRAB-PVQJCKRUSA-N Allantoin Natural products NC(=O)N[C@@H]1NC(=O)NC1=O POJWUDADGALRAB-PVQJCKRUSA-N 0.000 claims description 5
- 244000068988 Glycine max Species 0.000 claims description 5
- 235000010469 Glycine max Nutrition 0.000 claims description 5
- 241000186660 Lactobacillus Species 0.000 claims description 5
- 229920002125 Sokalan® Polymers 0.000 claims description 5
- 229960000458 allantoin Drugs 0.000 claims description 5
- CBTVGIZVANVGBH-UHFFFAOYSA-N aminomethyl propanol Chemical compound CC(C)(N)CO CBTVGIZVANVGBH-UHFFFAOYSA-N 0.000 claims description 5
- BQMNFPBUAQPINY-UHFFFAOYSA-N azane;2-methyl-2-(prop-2-enoylamino)propane-1-sulfonic acid Chemical compound [NH4+].[O-]S(=O)(=O)CC(C)(C)NC(=O)C=C BQMNFPBUAQPINY-UHFFFAOYSA-N 0.000 claims description 5
- 229960003237 betaine Drugs 0.000 claims description 5
- 229960001631 carbomer Drugs 0.000 claims description 5
- 238000012258 culturing Methods 0.000 claims description 5
- FHKSXSQHXQEMOK-UHFFFAOYSA-N hexane-1,2-diol Chemical compound CCCCC(O)CO FHKSXSQHXQEMOK-UHFFFAOYSA-N 0.000 claims description 5
- 239000003906 humectant Substances 0.000 claims description 5
- 229940039696 lactobacillus Drugs 0.000 claims description 5
- 229960005323 phenoxyethanol Drugs 0.000 claims description 5
- 229920000058 polyacrylate Polymers 0.000 claims description 5
- -1 polyethylene Polymers 0.000 claims description 5
- 229920000166 polytrimethylene carbonate Polymers 0.000 claims description 5
- 239000002244 precipitate Substances 0.000 claims description 5
- 239000003755 preservative agent Substances 0.000 claims description 5
- 239000002562 thickening agent Substances 0.000 claims description 5
- HIQIXEFWDLTDED-UHFFFAOYSA-N 4-hydroxy-1-piperidin-4-ylpyrrolidin-2-one Chemical compound O=C1CC(O)CN1C1CCNCC1 HIQIXEFWDLTDED-UHFFFAOYSA-N 0.000 claims description 4
- NLZUEZXRPGMBCV-UHFFFAOYSA-N Butylhydroxytoluene Chemical compound CC1=CC(C(C)(C)C)=C(O)C(C(C)(C)C)=C1 NLZUEZXRPGMBCV-UHFFFAOYSA-N 0.000 claims description 4
- ZAKOWWREFLAJOT-CEFNRUSXSA-N D-alpha-tocopherylacetate Chemical compound CC(=O)OC1=C(C)C(C)=C2O[C@@](CCC[C@H](C)CCC[C@H](C)CCCC(C)C)(C)CCC2=C1C ZAKOWWREFLAJOT-CEFNRUSXSA-N 0.000 claims description 4
- XMSXQFUHVRWGNA-UHFFFAOYSA-N Decamethylcyclopentasiloxane Chemical compound C[Si]1(C)O[Si](C)(C)O[Si](C)(C)O[Si](C)(C)O[Si](C)(C)O1 XMSXQFUHVRWGNA-UHFFFAOYSA-N 0.000 claims description 4
- IUMSDRXLFWAGNT-UHFFFAOYSA-N Dodecamethylcyclohexasiloxane Chemical compound C[Si]1(C)O[Si](C)(C)O[Si](C)(C)O[Si](C)(C)O[Si](C)(C)O[Si](C)(C)O1 IUMSDRXLFWAGNT-UHFFFAOYSA-N 0.000 claims description 4
- 229910021380 Manganese Chloride Inorganic materials 0.000 claims description 4
- GLFNIEUTAYBVOC-UHFFFAOYSA-L Manganese chloride Chemical compound Cl[Mn]Cl GLFNIEUTAYBVOC-UHFFFAOYSA-L 0.000 claims description 4
- 239000004698 Polyethylene Substances 0.000 claims description 4
- SZAMSYKZCSDVBH-CLFAGFIQSA-N [(z)-octadec-9-enyl] (z)-docos-13-enoate Chemical compound CCCCCCCC\C=C/CCCCCCCCCCCC(=O)OCCCCCCCC\C=C/CCCCCCCC SZAMSYKZCSDVBH-CLFAGFIQSA-N 0.000 claims description 4
- MTZQAGJQAFMTAQ-UHFFFAOYSA-N benzoic acid ethyl ester Natural products CCOC(=O)C1=CC=CC=C1 MTZQAGJQAFMTAQ-UHFFFAOYSA-N 0.000 claims description 4
- 229940086555 cyclomethicone Drugs 0.000 claims description 4
- ZAKOWWREFLAJOT-UHFFFAOYSA-N d-alpha-Tocopheryl acetate Natural products CC(=O)OC1=C(C)C(C)=C2OC(CCCC(C)CCCC(C)CCCC(C)C)(C)CCC2=C1C ZAKOWWREFLAJOT-UHFFFAOYSA-N 0.000 claims description 4
- 229940008099 dimethicone Drugs 0.000 claims description 4
- 239000004205 dimethyl polysiloxane Substances 0.000 claims description 4
- 235000013870 dimethyl polysiloxane Nutrition 0.000 claims description 4
- 238000001914 filtration Methods 0.000 claims description 4
- FOYKKGHVWRFIBD-UHFFFAOYSA-N gamma-tocopherol acetate Natural products CC(=O)OC1=C(C)C(C)=C2OC(CCCC(C)CCCC(C)CCCC(C)C)(C)CCC2=C1 FOYKKGHVWRFIBD-UHFFFAOYSA-N 0.000 claims description 4
- 125000003976 glyceryl group Chemical group [H]C([*])([H])C(O[H])([H])C(O[H])([H])[H] 0.000 claims description 4
- 238000003306 harvesting Methods 0.000 claims description 4
- 239000011565 manganese chloride Substances 0.000 claims description 4
- 235000002867 manganese chloride Nutrition 0.000 claims description 4
- 229940099607 manganese chloride Drugs 0.000 claims description 4
- WWZKQHOCKIZLMA-UHFFFAOYSA-N octanoic acid Chemical compound CCCCCCCC(O)=O WWZKQHOCKIZLMA-UHFFFAOYSA-N 0.000 claims description 4
- 229940120511 oleyl erucate Drugs 0.000 claims description 4
- 239000004006 olive oil Substances 0.000 claims description 4
- 235000008390 olive oil Nutrition 0.000 claims description 4
- 229920000435 poly(dimethylsiloxane) Polymers 0.000 claims description 4
- 229920000573 polyethylene Polymers 0.000 claims description 4
- 230000002335 preservative effect Effects 0.000 claims description 4
- 239000002904 solvent Substances 0.000 claims description 4
- LADGBHLMCUINGV-UHFFFAOYSA-N tricaprin Chemical compound CCCCCCCCCC(=O)OCC(OC(=O)CCCCCCCCC)COC(=O)CCCCCCCCC LADGBHLMCUINGV-UHFFFAOYSA-N 0.000 claims description 4
- 235000018936 Vitellaria paradoxa Nutrition 0.000 claims description 3
- 241001135917 Vitellaria paradoxa Species 0.000 claims description 3
- 125000003118 aryl group Chemical group 0.000 claims description 3
- CDQSJQSWAWPGKG-UHFFFAOYSA-N butane-1,1-diol Chemical compound CCCC(O)O CDQSJQSWAWPGKG-UHFFFAOYSA-N 0.000 claims description 3
- 238000007599 discharging Methods 0.000 claims description 3
- 235000019441 ethanol Nutrition 0.000 claims description 3
- 230000001376 precipitating effect Effects 0.000 claims description 3
- 238000010298 pulverizing process Methods 0.000 claims description 3
- 238000005086 pumping Methods 0.000 claims description 3
- 229940057910 shea butter Drugs 0.000 claims description 3
- UIIMBOGNXHQVGW-UHFFFAOYSA-M Sodium bicarbonate Chemical compound [Na+].OC([O-])=O UIIMBOGNXHQVGW-UHFFFAOYSA-M 0.000 claims description 2
- 239000000839 emulsion Substances 0.000 claims description 2
- KWIUHFFTVRNATP-UHFFFAOYSA-O N,N,N-trimethylglycinium Chemical compound C[N+](C)(C)CC(O)=O KWIUHFFTVRNATP-UHFFFAOYSA-O 0.000 claims 1
- 239000002537 cosmetic Substances 0.000 abstract description 9
- 230000002757 inflammatory effect Effects 0.000 abstract description 6
- 238000011161 development Methods 0.000 abstract description 4
- 238000004519 manufacturing process Methods 0.000 abstract description 4
- 206010013786 Dry skin Diseases 0.000 abstract description 3
- 230000037336 dry skin Effects 0.000 abstract description 3
- 208000024891 symptom Diseases 0.000 abstract description 3
- 210000003491 skin Anatomy 0.000 description 156
- MWUXSHHQAYIFBG-UHFFFAOYSA-N Nitric oxide Chemical compound O=[N] MWUXSHHQAYIFBG-UHFFFAOYSA-N 0.000 description 44
- 238000012360 testing method Methods 0.000 description 22
- 230000000694 effects Effects 0.000 description 19
- 210000004027 cell Anatomy 0.000 description 15
- 239000000243 solution Substances 0.000 description 15
- 239000000523 sample Substances 0.000 description 13
- 230000005764 inhibitory process Effects 0.000 description 12
- 210000002540 macrophage Anatomy 0.000 description 9
- 235000011187 glycerol Nutrition 0.000 description 7
- 235000018102 proteins Nutrition 0.000 description 7
- CURLTUGMZLYLDI-UHFFFAOYSA-N Carbon dioxide Chemical compound O=C=O CURLTUGMZLYLDI-UHFFFAOYSA-N 0.000 description 6
- KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 description 6
- 238000000605 extraction Methods 0.000 description 6
- 239000002689 soil Substances 0.000 description 6
- 239000002158 endotoxin Substances 0.000 description 5
- 229920006008 lipopolysaccharide Polymers 0.000 description 5
- 238000005406 washing Methods 0.000 description 5
- 230000000052 comparative effect Effects 0.000 description 4
- 230000006870 function Effects 0.000 description 4
- 229960005150 glycerol Drugs 0.000 description 4
- 239000001963 growth medium Substances 0.000 description 4
- 239000002609 medium Substances 0.000 description 4
- 239000000203 mixture Substances 0.000 description 4
- WWUZIQQURGPMPG-KRWOKUGFSA-N sphingosine Chemical compound CCCCCCCCCCCCC\C=C\[C@@H](O)[C@@H](N)CO WWUZIQQURGPMPG-KRWOKUGFSA-N 0.000 description 4
- 239000012224 working solution Substances 0.000 description 4
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 3
- KWYUFKZDYYNOTN-UHFFFAOYSA-M Potassium hydroxide Chemical compound [OH-].[K+] KWYUFKZDYYNOTN-UHFFFAOYSA-M 0.000 description 3
- 239000007864 aqueous solution Substances 0.000 description 3
- 239000001569 carbon dioxide Substances 0.000 description 3
- 229910002092 carbon dioxide Inorganic materials 0.000 description 3
- 230000003833 cell viability Effects 0.000 description 3
- 239000002738 chelating agent Substances 0.000 description 3
- 238000006243 chemical reaction Methods 0.000 description 3
- 230000003750 conditioning effect Effects 0.000 description 3
- 230000018109 developmental process Effects 0.000 description 3
- 210000000245 forearm Anatomy 0.000 description 3
- 238000004108 freeze drying Methods 0.000 description 3
- 238000011068 loading method Methods 0.000 description 3
- 238000005259 measurement Methods 0.000 description 3
- 235000016709 nutrition Nutrition 0.000 description 3
- 230000002829 reductive effect Effects 0.000 description 3
- 150000003839 salts Chemical class 0.000 description 3
- 239000004576 sand Substances 0.000 description 3
- PUPZLCDOIYMWBV-UHFFFAOYSA-N (+/-)-1,3-Butanediol Chemical compound CC(O)CCO PUPZLCDOIYMWBV-UHFFFAOYSA-N 0.000 description 2
- TXFPEBPIARQUIG-UHFFFAOYSA-N 4'-hydroxyacetophenone Chemical compound CC(=O)C1=CC=C(O)C=C1 TXFPEBPIARQUIG-UHFFFAOYSA-N 0.000 description 2
- JEBFVOLFMLUKLF-IFPLVEIFSA-N Astaxanthin Natural products CC(=C/C=C/C(=C/C=C/C1=C(C)C(=O)C(O)CC1(C)C)/C)C=CC=C(/C)C=CC=C(/C)C=CC2=C(C)C(=O)C(O)CC2(C)C JEBFVOLFMLUKLF-IFPLVEIFSA-N 0.000 description 2
- 239000004322 Butylated hydroxytoluene Substances 0.000 description 2
- 241000195649 Chlorella <Chlorellales> Species 0.000 description 2
- 238000002965 ELISA Methods 0.000 description 2
- 206010061218 Inflammation Diseases 0.000 description 2
- 241000736131 Sphingomonas Species 0.000 description 2
- 238000010521 absorption reaction Methods 0.000 description 2
- 239000003963 antioxidant agent Substances 0.000 description 2
- 235000006708 antioxidants Nutrition 0.000 description 2
- 238000003556 assay Methods 0.000 description 2
- 235000013793 astaxanthin Nutrition 0.000 description 2
- 239000001168 astaxanthin Substances 0.000 description 2
- MQZIGYBFDRPAKN-ZWAPEEGVSA-N astaxanthin Chemical compound C([C@H](O)C(=O)C=1C)C(C)(C)C=1/C=C/C(/C)=C/C=C/C(/C)=C/C=C/C=C(C)C=CC=C(C)C=CC1=C(C)C(=O)[C@@H](O)CC1(C)C MQZIGYBFDRPAKN-ZWAPEEGVSA-N 0.000 description 2
- 229940022405 astaxanthin Drugs 0.000 description 2
- WPYMKLBDIGXBTP-UHFFFAOYSA-N benzoic acid Chemical compound OC(=O)C1=CC=CC=C1 WPYMKLBDIGXBTP-UHFFFAOYSA-N 0.000 description 2
- 230000015572 biosynthetic process Effects 0.000 description 2
- 235000010354 butylated hydroxytoluene Nutrition 0.000 description 2
- 229940095259 butylated hydroxytoluene Drugs 0.000 description 2
- 230000007910 cell fusion Effects 0.000 description 2
- 230000008859 change Effects 0.000 description 2
- 231100000263 cytotoxicity test Toxicity 0.000 description 2
- SZXQTJUDPRGNJN-UHFFFAOYSA-N dipropylene glycol Chemical compound OCCCOCCCO SZXQTJUDPRGNJN-UHFFFAOYSA-N 0.000 description 2
- 229940113120 dipropylene glycol Drugs 0.000 description 2
- 238000002474 experimental method Methods 0.000 description 2
- 235000013305 food Nutrition 0.000 description 2
- 238000009472 formulation Methods 0.000 description 2
- 239000003205 fragrance Substances 0.000 description 2
- 239000000499 gel Substances 0.000 description 2
- 238000005286 illumination Methods 0.000 description 2
- 230000006872 improvement Effects 0.000 description 2
- 238000011534 incubation Methods 0.000 description 2
- 230000004054 inflammatory process Effects 0.000 description 2
- 239000000463 material Substances 0.000 description 2
- LXCFILQKKLGQFO-UHFFFAOYSA-N methylparaben Chemical compound COC(=O)C1=CC=C(O)C=C1 LXCFILQKKLGQFO-UHFFFAOYSA-N 0.000 description 2
- 239000011259 mixed solution Substances 0.000 description 2
- 230000004048 modification Effects 0.000 description 2
- 238000012986 modification Methods 0.000 description 2
- 238000004806 packaging method and process Methods 0.000 description 2
- 239000002304 perfume Substances 0.000 description 2
- 230000002265 prevention Effects 0.000 description 2
- 230000001737 promoting effect Effects 0.000 description 2
- QELSKZZBTMNZEB-UHFFFAOYSA-N propylparaben Chemical compound CCCOC(=O)C1=CC=C(O)C=C1 QELSKZZBTMNZEB-UHFFFAOYSA-N 0.000 description 2
- 238000011160 research Methods 0.000 description 2
- 230000009759 skin aging Effects 0.000 description 2
- 239000011734 sodium Substances 0.000 description 2
- PRAKJMSDJKAYCZ-UHFFFAOYSA-N squalane Chemical compound CC(C)CCCC(C)CCCC(C)CCCCC(C)CCCC(C)CCCC(C)C PRAKJMSDJKAYCZ-UHFFFAOYSA-N 0.000 description 2
- 230000035882 stress Effects 0.000 description 2
- 230000035899 viability Effects 0.000 description 2
- HDTRYLNUVZCQOY-UHFFFAOYSA-N α-D-glucopyranosyl-α-D-glucopyranoside Natural products OC1C(O)C(O)C(CO)OC1OC1C(O)C(O)C(O)C(CO)O1 HDTRYLNUVZCQOY-UHFFFAOYSA-N 0.000 description 1
- LODWEXDBRZBADB-XEVVZDEMSA-N (2s)-6-amino-2-[[(2s)-2-[[(2s)-6-amino-2-(hexadecanoylamino)hexanoyl]amino]-3-methylbutanoyl]amino]hexanoic acid Chemical compound CCCCCCCCCCCCCCCC(=O)N[C@@H](CCCCN)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CCCCN)C(O)=O LODWEXDBRZBADB-XEVVZDEMSA-N 0.000 description 1
- FYGDTMLNYKFZSV-URKRLVJHSA-N (2s,3r,4s,5s,6r)-2-[(2r,4r,5r,6s)-4,5-dihydroxy-2-(hydroxymethyl)-6-[(2r,4r,5r,6s)-4,5,6-trihydroxy-2-(hydroxymethyl)oxan-3-yl]oxyoxan-3-yl]oxy-6-(hydroxymethyl)oxane-3,4,5-triol Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@H]1OC1[C@@H](CO)O[C@@H](OC2[C@H](O[C@H](O)[C@H](O)[C@H]2O)CO)[C@H](O)[C@H]1O FYGDTMLNYKFZSV-URKRLVJHSA-N 0.000 description 1
- MZOFCQQQCNRIBI-VMXHOPILSA-N (3s)-4-[[(2s)-1-[[(2s)-1-[[(1s)-1-carboxy-2-hydroxyethyl]amino]-4-methyl-1-oxopentan-2-yl]amino]-5-(diaminomethylideneamino)-1-oxopentan-2-yl]amino]-3-[[2-[[(2s)-2,6-diaminohexanoyl]amino]acetyl]amino]-4-oxobutanoic acid Chemical compound OC[C@@H](C(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCCN=C(N)N)NC(=O)[C@H](CC(O)=O)NC(=O)CNC(=O)[C@@H](N)CCCCN MZOFCQQQCNRIBI-VMXHOPILSA-N 0.000 description 1
- 229940083957 1,2-butanediol Drugs 0.000 description 1
- XDOFQFKRPWOURC-UHFFFAOYSA-N 16-methylheptadecanoic acid Chemical compound CC(C)CCCCCCCCCCCCCCC(O)=O XDOFQFKRPWOURC-UHFFFAOYSA-N 0.000 description 1
- OMIGHNLMNHATMP-UHFFFAOYSA-N 2-hydroxyethyl prop-2-enoate Chemical compound OCCOC(=O)C=C OMIGHNLMNHATMP-UHFFFAOYSA-N 0.000 description 1
- NIXOWILDQLNWCW-UHFFFAOYSA-M Acrylate Chemical compound [O-]C(=O)C=C NIXOWILDQLNWCW-UHFFFAOYSA-M 0.000 description 1
- 239000004475 Arginine Substances 0.000 description 1
- 240000002900 Arthrospira platensis Species 0.000 description 1
- 235000016425 Arthrospira platensis Nutrition 0.000 description 1
- 239000005711 Benzoic acid Substances 0.000 description 1
- 229920002498 Beta-glucan Polymers 0.000 description 1
- 239000002028 Biomass Substances 0.000 description 1
- 102000008186 Collagen Human genes 0.000 description 1
- 108010035532 Collagen Proteins 0.000 description 1
- FBPFZTCFMRRESA-FSIIMWSLSA-N D-Glucitol Natural products OC[C@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-FSIIMWSLSA-N 0.000 description 1
- FBPFZTCFMRRESA-JGWLITMVSA-N D-glucitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-JGWLITMVSA-N 0.000 description 1
- SBJKKFFYIZUCET-JLAZNSOCSA-N Dehydro-L-ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(=O)C(=O)C1=O SBJKKFFYIZUCET-JLAZNSOCSA-N 0.000 description 1
- 201000004624 Dermatitis Diseases 0.000 description 1
- 206010012442 Dermatitis contact Diseases 0.000 description 1
- 240000000902 Diospyros discolor Species 0.000 description 1
- 235000003115 Diospyros discolor Nutrition 0.000 description 1
- 108010016626 Dipeptides Proteins 0.000 description 1
- ZGTMUACCHSMWAC-UHFFFAOYSA-L EDTA disodium salt (anhydrous) Chemical compound [Na+].[Na+].OC(=O)CN(CC([O-])=O)CCN(CC(O)=O)CC([O-])=O ZGTMUACCHSMWAC-UHFFFAOYSA-L 0.000 description 1
- 102000004190 Enzymes Human genes 0.000 description 1
- 108090000790 Enzymes Proteins 0.000 description 1
- 241000168525 Haematococcus Species 0.000 description 1
- 229920000663 Hydroxyethyl cellulose Polymers 0.000 description 1
- 239000004354 Hydroxyethyl cellulose Substances 0.000 description 1
- 108090001005 Interleukin-6 Proteins 0.000 description 1
- ODKSFYDXXFIFQN-BYPYZUCNSA-P L-argininium(2+) Chemical compound NC(=[NH2+])NCCC[C@H]([NH3+])C(O)=O ODKSFYDXXFIFQN-BYPYZUCNSA-P 0.000 description 1
- 241000199919 Phaeophyceae Species 0.000 description 1
- 229920001213 Polysorbate 20 Polymers 0.000 description 1
- 238000012356 Product development Methods 0.000 description 1
- 241000316848 Rhodococcus <scale insect> Species 0.000 description 1
- 241000206572 Rhodophyta Species 0.000 description 1
- 240000004808 Saccharomyces cerevisiae Species 0.000 description 1
- 241000195474 Sargassum Species 0.000 description 1
- 208000028990 Skin injury Diseases 0.000 description 1
- 229920002385 Sodium hyaluronate Polymers 0.000 description 1
- HDTRYLNUVZCQOY-WSWWMNSNSA-N Trehalose Natural products O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@@H]1O[C@@H]1[C@H](O)[C@@H](O)[C@@H](O)[C@@H](CO)O1 HDTRYLNUVZCQOY-WSWWMNSNSA-N 0.000 description 1
- 108060008682 Tumor Necrosis Factor Proteins 0.000 description 1
- 102000000852 Tumor Necrosis Factor-alpha Human genes 0.000 description 1
- 241000196252 Ulva Species 0.000 description 1
- 238000002835 absorbance Methods 0.000 description 1
- 230000002378 acidificating effect Effects 0.000 description 1
- 239000013543 active substance Substances 0.000 description 1
- 239000000654 additive Substances 0.000 description 1
- 230000000996 additive effect Effects 0.000 description 1
- 230000032683 aging Effects 0.000 description 1
- 239000003513 alkali Substances 0.000 description 1
- OENHQHLEOONYIE-UKMVMLAPSA-N all-trans beta-carotene Natural products CC=1CCCC(C)(C)C=1/C=C/C(/C)=C/C=C/C(/C)=C/C=C/C=C(C)C=CC=C(C)C=CC1=C(C)CCCC1(C)C OENHQHLEOONYIE-UKMVMLAPSA-N 0.000 description 1
- HDTRYLNUVZCQOY-LIZSDCNHSA-N alpha,alpha-trehalose Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@@H]1O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 HDTRYLNUVZCQOY-LIZSDCNHSA-N 0.000 description 1
- FRHBOQMZUOWXQL-UHFFFAOYSA-L ammonium ferric citrate Chemical compound [NH4+].[Fe+3].[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O FRHBOQMZUOWXQL-UHFFFAOYSA-L 0.000 description 1
- 230000003471 anti-radiation Effects 0.000 description 1
- 230000000259 anti-tumor effect Effects 0.000 description 1
- 230000002155 anti-virotic effect Effects 0.000 description 1
- 239000000427 antigen Substances 0.000 description 1
- 102000036639 antigens Human genes 0.000 description 1
- 108091007433 antigens Proteins 0.000 description 1
- 230000003078 antioxidant effect Effects 0.000 description 1
- ODKSFYDXXFIFQN-UHFFFAOYSA-N arginine Natural products OC(=O)C(N)CCCNC(N)=N ODKSFYDXXFIFQN-UHFFFAOYSA-N 0.000 description 1
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 1
- 230000001580 bacterial effect Effects 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- 230000008901 benefit Effects 0.000 description 1
- 235000010233 benzoic acid Nutrition 0.000 description 1
- 229960004365 benzoic acid Drugs 0.000 description 1
- 235000013734 beta-carotene Nutrition 0.000 description 1
- TUPZEYHYWIEDIH-WAIFQNFQSA-N beta-carotene Natural products CC(=C/C=C/C=C(C)/C=C/C=C(C)/C=C/C1=C(C)CCCC1(C)C)C=CC=C(/C)C=CC2=CCCCC2(C)C TUPZEYHYWIEDIH-WAIFQNFQSA-N 0.000 description 1
- 239000011648 beta-carotene Substances 0.000 description 1
- 229960002747 betacarotene Drugs 0.000 description 1
- 230000000975 bioactive effect Effects 0.000 description 1
- 210000004369 blood Anatomy 0.000 description 1
- 239000008280 blood Substances 0.000 description 1
- 150000001720 carbohydrates Chemical class 0.000 description 1
- 235000014633 carbohydrates Nutrition 0.000 description 1
- 239000004359 castor oil Substances 0.000 description 1
- 235000019438 castor oil Nutrition 0.000 description 1
- 238000004113 cell culture Methods 0.000 description 1
- 238000005119 centrifugation Methods 0.000 description 1
- 229940099417 ceramide 2 Drugs 0.000 description 1
- 239000003153 chemical reaction reagent Substances 0.000 description 1
- SOYKEARSMXGVTM-UHFFFAOYSA-N chlorphenamine Chemical compound C=1C=CC=NC=1C(CCN(C)C)C1=CC=C(Cl)C=C1 SOYKEARSMXGVTM-UHFFFAOYSA-N 0.000 description 1
- 229960003291 chlorphenamine Drugs 0.000 description 1
- 229920001436 collagen Polymers 0.000 description 1
- 239000002131 composite material Substances 0.000 description 1
- 150000001875 compounds Chemical class 0.000 description 1
- 208000010247 contact dermatitis Diseases 0.000 description 1
- 229920006037 cross link polymer Polymers 0.000 description 1
- 239000012228 culture supernatant Substances 0.000 description 1
- 231100000433 cytotoxic Toxicity 0.000 description 1
- 230000001472 cytotoxic effect Effects 0.000 description 1
- 231100000135 cytotoxicity Toxicity 0.000 description 1
- 230000003013 cytotoxicity Effects 0.000 description 1
- 238000005238 degreasing Methods 0.000 description 1
- 239000008367 deionised water Substances 0.000 description 1
- 229910021641 deionized water Inorganic materials 0.000 description 1
- 230000008021 deposition Effects 0.000 description 1
- 150000004985 diamines Chemical class 0.000 description 1
- 150000008049 diazo compounds Chemical class 0.000 description 1
- 125000000664 diazo group Chemical group [N-]=[N+]=[*] 0.000 description 1
- 239000012954 diazonium Substances 0.000 description 1
- 150000001989 diazonium salts Chemical class 0.000 description 1
- 235000005911 diet Nutrition 0.000 description 1
- 230000000378 dietary effect Effects 0.000 description 1
- 235000014113 dietary fatty acids Nutrition 0.000 description 1
- MBMBGCFOFBJSGT-KUBAVDMBSA-N docosahexaenoic acid Natural products CC\C=C/C\C=C/C\C=C/C\C=C/C\C=C/C\C=C/CCC(O)=O MBMBGCFOFBJSGT-KUBAVDMBSA-N 0.000 description 1
- 235000020669 docosahexaenoic acid Nutrition 0.000 description 1
- 229940079593 drug Drugs 0.000 description 1
- 239000003814 drug Substances 0.000 description 1
- 235000020673 eicosapentaenoic acid Nutrition 0.000 description 1
- 239000003480 eluent Substances 0.000 description 1
- 239000003995 emulsifying agent Substances 0.000 description 1
- 230000007613 environmental effect Effects 0.000 description 1
- 238000012869 ethanol precipitation Methods 0.000 description 1
- BEFDCLMNVWHSGT-UHFFFAOYSA-N ethenylcyclopentane Chemical compound C=CC1CCCC1 BEFDCLMNVWHSGT-UHFFFAOYSA-N 0.000 description 1
- 239000000194 fatty acid Substances 0.000 description 1
- 229930195729 fatty acid Natural products 0.000 description 1
- 150000004665 fatty acids Chemical class 0.000 description 1
- 229960004642 ferric ammonium citrate Drugs 0.000 description 1
- 239000000706 filtrate Substances 0.000 description 1
- ZEMPKEQAKRGZGQ-XOQCFJPHSA-N glycerol triricinoleate Natural products CCCCCC[C@@H](O)CC=CCCCCCCCC(=O)OC[C@@H](COC(=O)CCCCCCCC=CC[C@@H](O)CCCCCC)OC(=O)CCCCCCCC=CC[C@H](O)CCCCCC ZEMPKEQAKRGZGQ-XOQCFJPHSA-N 0.000 description 1
- 239000004519 grease Substances 0.000 description 1
- 230000036541 health Effects 0.000 description 1
- 235000019447 hydroxyethyl cellulose Nutrition 0.000 description 1
- 230000007365 immunoregulation Effects 0.000 description 1
- 238000000338 in vitro Methods 0.000 description 1
- 238000001727 in vivo Methods 0.000 description 1
- 239000003112 inhibitor Substances 0.000 description 1
- 238000011081 inoculation Methods 0.000 description 1
- 229910052500 inorganic mineral Inorganic materials 0.000 description 1
- 238000007689 inspection Methods 0.000 description 1
- 239000004313 iron ammonium citrate Substances 0.000 description 1
- 235000000011 iron ammonium citrate Nutrition 0.000 description 1
- 208000032839 leukemia Diseases 0.000 description 1
- 230000000670 limiting effect Effects 0.000 description 1
- 239000007788 liquid Substances 0.000 description 1
- 239000006210 lotion Substances 0.000 description 1
- 239000006166 lysate Substances 0.000 description 1
- 230000003211 malignant effect Effects 0.000 description 1
- 239000004292 methyl p-hydroxybenzoate Substances 0.000 description 1
- 235000010270 methyl p-hydroxybenzoate Nutrition 0.000 description 1
- 229960002216 methylparaben Drugs 0.000 description 1
- 244000005700 microbiome Species 0.000 description 1
- 239000012982 microporous membrane Substances 0.000 description 1
- 235000010755 mineral Nutrition 0.000 description 1
- 239000011707 mineral Substances 0.000 description 1
- 210000001616 monocyte Anatomy 0.000 description 1
- JXTPJDDICSTXJX-UHFFFAOYSA-N n-Triacontane Natural products CCCCCCCCCCCCCCCCCCCCCCCCCCCCCC JXTPJDDICSTXJX-UHFFFAOYSA-N 0.000 description 1
- 235000015097 nutrients Nutrition 0.000 description 1
- 230000035764 nutrition Effects 0.000 description 1
- 230000003287 optical effect Effects 0.000 description 1
- 230000003647 oxidation Effects 0.000 description 1
- 238000007254 oxidation reaction Methods 0.000 description 1
- 229910052760 oxygen Inorganic materials 0.000 description 1
- 239000001301 oxygen Substances 0.000 description 1
- 239000003002 pH adjusting agent Substances 0.000 description 1
- 229940094912 palmitoyl tripeptide-5 Drugs 0.000 description 1
- WCVRQHFDJLLWFE-UHFFFAOYSA-N pentane-1,2-diol Chemical compound CCCC(O)CO WCVRQHFDJLLWFE-UHFFFAOYSA-N 0.000 description 1
- 230000000144 pharmacologic effect Effects 0.000 description 1
- 229920003023 plastic Polymers 0.000 description 1
- 239000004033 plastic Substances 0.000 description 1
- 229940070721 polyacrylate Drugs 0.000 description 1
- 239000000256 polyoxyethylene sorbitan monolaurate Substances 0.000 description 1
- 235000010486 polyoxyethylene sorbitan monolaurate Nutrition 0.000 description 1
- 229940068977 polysorbate 20 Drugs 0.000 description 1
- 229940054168 pomegranate fruit extract Drugs 0.000 description 1
- 239000013641 positive control Substances 0.000 description 1
- 229940078492 ppg-17 Drugs 0.000 description 1
- 230000008569 process Effects 0.000 description 1
- 235000010232 propyl p-hydroxybenzoate Nutrition 0.000 description 1
- 239000004405 propyl p-hydroxybenzoate Substances 0.000 description 1
- 229960003415 propylparaben Drugs 0.000 description 1
- 238000011403 purification operation Methods 0.000 description 1
- 230000005855 radiation Effects 0.000 description 1
- 230000009467 reduction Effects 0.000 description 1
- 238000007789 sealing Methods 0.000 description 1
- 230000003248 secreting effect Effects 0.000 description 1
- 230000037307 sensitive skin Effects 0.000 description 1
- 230000035945 sensitivity Effects 0.000 description 1
- 210000004927 skin cell Anatomy 0.000 description 1
- 239000001509 sodium citrate Substances 0.000 description 1
- NLJMYIDDQXHKNR-UHFFFAOYSA-K sodium citrate Chemical compound O.O.[Na+].[Na+].[Na+].[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O NLJMYIDDQXHKNR-UHFFFAOYSA-K 0.000 description 1
- 229940010747 sodium hyaluronate Drugs 0.000 description 1
- YWIVKILSMZOHHF-QJZPQSOGSA-N sodium;(2s,3s,4s,5r,6r)-6-[(2s,3r,4r,5s,6r)-3-acetamido-2-[(2s,3s,4r,5r,6r)-6-[(2r,3r,4r,5s,6r)-3-acetamido-2,5-dihydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-2-carboxy-4,5-dihydroxyoxan-3-yl]oxy-5-hydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-3,4,5-trihydroxyoxane-2- Chemical compound [Na+].CC(=O)N[C@H]1[C@H](O)O[C@H](CO)[C@@H](O)[C@@H]1O[C@H]1[C@H](O)[C@@H](O)[C@H](O[C@H]2[C@@H]([C@@H](O[C@H]3[C@@H]([C@@H](O)[C@H](O)[C@H](O3)C(O)=O)O)[C@H](O)[C@@H](CO)O2)NC(C)=O)[C@@H](C(O)=O)O1 YWIVKILSMZOHHF-QJZPQSOGSA-N 0.000 description 1
- 235000010199 sorbic acid Nutrition 0.000 description 1
- 239000004334 sorbic acid Substances 0.000 description 1
- 229940075582 sorbic acid Drugs 0.000 description 1
- 239000000600 sorbitol Substances 0.000 description 1
- 229960002920 sorbitol Drugs 0.000 description 1
- 235000010356 sorbitol Nutrition 0.000 description 1
- 241000894007 species Species 0.000 description 1
- 230000003595 spectral effect Effects 0.000 description 1
- 229940082787 spirulina Drugs 0.000 description 1
- 230000007480 spreading Effects 0.000 description 1
- 238000003892 spreading Methods 0.000 description 1
- 229940032094 squalane Drugs 0.000 description 1
- 230000000638 stimulation Effects 0.000 description 1
- 239000011550 stock solution Substances 0.000 description 1
- 229940124530 sulfonamide Drugs 0.000 description 1
- 150000003456 sulfonamides Chemical class 0.000 description 1
- 239000013589 supplement Substances 0.000 description 1
- 238000003786 synthesis reaction Methods 0.000 description 1
- 238000010998 test method Methods 0.000 description 1
- UEUXEKPTXMALOB-UHFFFAOYSA-J tetrasodium;2-[2-[bis(carboxylatomethyl)amino]ethyl-(carboxylatomethyl)amino]acetate Chemical compound [Na+].[Na+].[Na+].[Na+].[O-]C(=O)CN(CC([O-])=O)CCN(CC([O-])=O)CC([O-])=O UEUXEKPTXMALOB-UHFFFAOYSA-J 0.000 description 1
- 231100000331 toxic Toxicity 0.000 description 1
- 230000002588 toxic effect Effects 0.000 description 1
- 230000008728 vascular permeability Effects 0.000 description 1
- 235000013343 vitamin Nutrition 0.000 description 1
- 239000011782 vitamin Substances 0.000 description 1
- 229940088594 vitamin Drugs 0.000 description 1
- 229930003231 vitamin Natural products 0.000 description 1
- 230000037303 wrinkles Effects 0.000 description 1
- 239000000230 xanthan gum Substances 0.000 description 1
- 229920001285 xanthan gum Polymers 0.000 description 1
- 235000010493 xanthan gum Nutrition 0.000 description 1
- 229940082509 xanthan gum Drugs 0.000 description 1
- OENHQHLEOONYIE-JLTXGRSLSA-N β-Carotene Chemical compound CC=1CCCC(C)(C)C=1\C=C\C(\C)=C\C=C\C(\C)=C\C=C\C=C(/C)\C=C\C=C(/C)\C=C\C1=C(C)CCCC1(C)C OENHQHLEOONYIE-JLTXGRSLSA-N 0.000 description 1
Images
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/72—Cosmetics or similar toiletry preparations characterised by the composition containing organic macromolecular compounds
- A61K8/73—Polysaccharides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/96—Cosmetics or similar toiletry preparations characterised by the composition containing materials, or derivatives thereof of undetermined constitution
- A61K8/99—Cosmetics or similar toiletry preparations characterised by the composition containing materials, or derivatives thereof of undetermined constitution from microorganisms other than algae or fungi, e.g. protozoa or bacteria
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
- A61Q19/00—Preparations for care of the skin
-
- C—CHEMISTRY; METALLURGY
- C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
- C08B—POLYSACCHARIDES; DERIVATIVES THEREOF
- C08B37/00—Preparation of polysaccharides not provided for in groups C08B1/00 - C08B35/00; Derivatives thereof
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Chemical & Material Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Organic Chemistry (AREA)
- Epidemiology (AREA)
- Birds (AREA)
- Medicinal Chemistry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Engineering & Computer Science (AREA)
- Biochemistry (AREA)
- Pain & Pain Management (AREA)
- Materials Engineering (AREA)
- Dermatology (AREA)
- Tropical Medicine & Parasitology (AREA)
- Polymers & Plastics (AREA)
- Biotechnology (AREA)
- Molecular Biology (AREA)
- Rheumatology (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pharmacology & Pharmacy (AREA)
- Cosmetics (AREA)
- Medicines Containing Plant Substances (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Abstract
本发明公开了沙漠藻护肤原料在制备皮肤舒缓剂中的应用,涉及具鞘微鞘藻应用技术领域。本发明所选的沙漠藻护肤原料分离自沙漠干旱地区,其具有强皮肤舒缓能力,作为皮肤舒缓剂生产应用具有开发价值,同时本发明所选的沙漠藻护肤原料还可以显著抑制巨噬细胞炎症因子释放,同时显著降低皮肤血红素,其可广泛应用于护肤品或化妆品中作为舒缓剂使用。本发明的护肤品,以沙漠藻护肤原料为皮肤舒缓剂,降低炎症因子的释放,抑制外界刺激引起的皮肤血红素的增加,改善皮肤特别是干皮的症状。
Description
技术领域
本发明涉及具鞘微鞘藻应用技术领域,具体而言,涉及沙漠藻护肤原料在制备皮肤舒缓剂中的应用。
背景技术
微藻富含碳水化合物、蛋白质、维生素、矿物质等多种能量和营养物质,如螺旋藻和小球藻中蛋白质含量一般可以到达细胞干重的50-70%。多种微藻已被列入我国新资源食品和普通食品行列,以微藻培养及其产物开发利用为主体的微藻生物技术是人们解决粮食、能源、环保和医药等问题的有效途径之一。
微藻中的生物活性物质,如虾青素、β-胡萝卜素、DHA、EPA等常被提取出来,精制后做成胶囊。其中,虾青素被誉为“抗氧化剂之王”,具有清除人体内氧自由基的功效,由于强大的抗氧化性能,虾青素添加到护肤品,具有抗皱纹及皮肤老化、抗晒、防紫外等作用。同时,微藻提取混合物,主要有蛋白、脂肪酸、多糖等也常作为护肤和药妆品的添加剂,具有清除老化皮肤细胞,保持皮肤健康的功能。近年来,沙漠地区微藻的研究及应用引起广泛关注和重视。沙漠藻的生长环境(极度干旱、温差巨大、日照强烈、土壤贫瘠)决定了其细胞的特殊营养价值、提高了细胞抗逆成分的活性、进化了细胞的生存能力及自我保护形式。在微藻资源中,沙漠藻类被认为是一种非常有前景的生物资源,其开发应用研究亟待加强。
具鞘微鞘藻是荒漠土壤中分布最为广泛的荒漠藻类物种之一,其生物量有时高达土壤微生物总量的95%以上。近年来,具鞘微鞘藻在荒漠化治理中显示出良好的应用潜力,具备水土保持、土壤改良、防风固沙等优良的生态功能,是固定流沙的重要藻种和生物固沙的重要方法之一。如已公开的中国专利102199542A描述了一种从荒漠生物结皮中分离和纯化具鞘微鞘藻的方法。具鞘微鞘藻除具有优良的固沙结皮功能外,其藻细胞中还含有丰富的多糖组分,是一种优良的高产藻多糖的微藻资源。
沙漠藻的生长环境(极度干旱、温差巨大、日照强烈、土壤贫瘠)决定了具鞘微鞘藻的特殊营养价值、提高了细胞抗逆成分的活性、进化了细胞的生存能力及自我保护形式。具鞘微鞘藻提取物具有免疫调节、抗肿瘤、抗病毒、抗辐射等多种药理作用,而几乎没有毒副作用。另外具鞘微鞘藻多糖在膳食营养、保健调理、预防衰老等方面的作用也逐渐被人们所认识,具鞘微鞘藻的开发和利用展现出诱人的前景。
但是鲜有具鞘微鞘藻外用于皮肤被报道的功效,从而导致具鞘微鞘藻应用于化妆品的范围亦有限。
鉴于此,特提出本发明。
发明内容
本发明的目的在于提供沙漠藻护肤原料在制备皮肤舒缓剂中的应用。
本发明是这样实现的:
第一方面,本发明提供一种沙漠藻护肤原料在制备皮肤舒缓剂中的应用,所述沙漠藻护肤原料为具鞘微鞘藻多糖,所述皮肤舒缓剂为抑制巨噬细胞炎症因子释放和降低皮肤血红素含量的试剂。
在可选的实施方式中,所述沙漠藻护肤原料在所述皮肤舒缓剂中的浓度为0.25mg/mL-5 mg/mL,所述沙漠藻护肤原料抑制巨噬细胞炎症因子的抑制率为6.1%-74.6%。
在可选的实施方式中,所述沙漠藻护肤原料在所述皮肤舒缓剂中的浓度为2.5mg/mL-5 mg/mL,所述沙漠藻护肤原料抑制巨噬细胞炎症因子的抑制率为46.4%-74.6%。
在可选的实施方式中,所述沙漠藻护肤原料在所述皮肤舒缓剂中的浓度为0.5%-20%时,所述沙漠藻护肤原料降低舒缓刺激模型皮肤血红素含量的降低率为54.35%-85.19%。
在可选的实施方式中,所述沙漠藻护肤原料的制备方法其包括:
对具鞘微鞘藻经培养、采收后进行干燥、制粉得到具鞘微鞘藻粉末;
对所述具鞘微鞘藻粉末加入第一无水乙醇,进行摇床震荡,随后过滤得到藻体;
将所述藻体重新分散在水中,热碱法浸提,离心收集上清,重复提取三次,合并上清液后加入第二无水乙醇,低温醇沉,离心收集沉淀,干燥得到具鞘微鞘藻粗提取;
将所述具鞘微鞘藻粗提取重新溶解于水,采用丙酮洗涤去色素,接着采用氯仿-正丁醇去蛋白,得到具鞘微鞘藻多糖,即为所述沙漠藻护肤原料。
在可选的实施方式中,所述具鞘微鞘藻粉末与所述第一无水乙醇的料液比为1:20-30,所述热碱法浸提包括采用2wt%-3 wt%的NaOH调pH至9-11,65-75℃热水浸提3-4h;所述上清液与所述第二无水乙醇的体积比为1:3-5;所述氯仿-正丁醇中氯仿和正丁醇的混合体积比为3-5:1。
第二方面,本发明提供一种护肤品,其组分按质量百分比计包括:保湿剂0.01-20%、增稠剂0.02-0.8%、PH调节剂0.01-1%、防腐剂0.01-0.15%、皮肤调理剂0.01-5%、增溶剂0.01-0.5%、芳香剂0.005-0.5%、皮肤舒缓剂0.01-20%和余量的水,其中,所述皮肤舒缓剂为上述沙漠藻护肤原料在制备皮肤舒缓剂中的应用的所述沙漠藻护肤原料。
在可选的实施方式中,所述护肤品包括水剂、乳液、膏霜或凝露。
第三方面,本发明提供一种舒缓霜,其组分包括A相、B相、C相和D相,按质量百分数计:
所述A相包括肉豆蔻酸异丙酯3.00%、环聚二甲基硅氧烷2.00%、辛酸/癸酸甘油三酯3.00%、油醇芥酸酯2.00%、环己硅氧烷1.00%、聚甘油-3 甲基葡糖二硬脂酸酯1.50%、牛油果树果脂2.00%、聚二甲基硅氧烷3.00%、聚丙烯酰胺和月桂醇聚醚-7和C13-14异链烷烃的复合物0.30%、C12-15 醇苯甲酸酯1.00%、PEG-100 硬脂酸酯和甘油硬脂酸酯的复合物1.00%、生育酚乙酸酯0.30%、油橄榄油不皂化物0.20%、甘油聚丙烯酸酯2.00%、丙烯酰二甲基牛磺酸铵/VP共聚物0.40%、丁羟甲苯0.05%、香精0.18%;
所述B相包括余量的水、甘油3.00%、1,3-丙二醇1.00%、泛醇1.00%、甜菜碱1.00%、氨甲基丙醇0.12%、尿囊素0.10%、卡波姆0.20%、氯化锰0.01%;
所述C相包括聚乙二醇-90M 2.00%、丁二醇3.00%;
所述D相包括上述沙漠藻护肤原料在制备皮肤舒缓剂中的应用的所述沙漠藻护肤原料0.5%-20%、苯氧乙醇0.40%、1,2-己二醇0.40%、乳酸杆菌/大豆发酵产物提取物0.50%;
所述舒缓霜的制备方法包括:
将所述A相加入油相锅,搅拌并加热至80-85℃,使之充分溶解;
将所述B相加入乳化锅,搅拌并加热到80-85℃,使之充分溶解;
将所述油相锅内油相物质慢慢抽到所述乳化锅,搅拌、均质、真空乳化,保持乳化锅温度为80-85℃;
降温至42℃,加入所述C相和所述D相搅拌均匀;冷却至37℃,出料,静置24小时。
本发明具有以下有益效果:本发明所选的沙漠藻护肤原料,其具有强皮肤舒缓能力,作为皮肤舒缓剂生产应用具有开发价值,同时本发明所选的沙漠藻护肤原料还可以显著抑制巨噬细胞炎症因子释放,同时显著降低皮肤血红素含量,其可广泛应用于护肤品或化妆品中作为舒缓剂使用。本发明的护肤品,以沙漠藻护肤原料为皮肤舒缓剂,降低炎症因子的释放,抑制外界刺激引起的皮肤血红素的增加,改善皮肤特别是干皮的症状。
附图说明
为了更清楚地说明本发明实施例的技术方案,下面将对实施例中所需要使用的附图作简单地介绍,应当理解,以下附图仅示出了本发明的某些实施例,因此不应被看作是对范围的限定,对于本领域普通技术人员来讲,在不付出创造性劳动的前提下,还可以根据这些附图获得其他相关的附图。
图1为本申请提供的不同浓度的具鞘微鞘藻抑制巨噬细胞炎症因子释放的测试结果;
图2为本申请提供的不同藻提取物抑制巨噬细胞炎症因子释放的效果对比图;
图3为本申请提供的抗刺激试验皮肤血红素含量比较图;
图4为本申请提供的舒缓刺激试验皮肤血红素含量比较图。
具体实施方式
为使本发明实施例的目的、技术方案和优点更加清楚,下面将对本发明实施例中的技术方案进行清楚、完整地描述。实施例中未注明具体条件者,按照常规条件或制造商建议的条件进行。所用试剂或仪器未注明生产厂商者,均为可以通过市售购买获得的常规产品。
本发明的具鞘微鞘藻分离自中国沙漠干旱地区,具鞘微鞘藻能在荒漠地区严酷(干旱、强辐射、温度剧烈变化以及高盐碱)的环境下生长繁殖,通过分泌胞外多糖和施加机械束缚力形成生物结皮,用于防沙治沙,促进荒漠地区的生态修复。
据此,本申请提供了一种沙漠藻护肤原料的新应用,新应用例如包括沙漠藻护肤原料在制备皮肤舒缓剂中的应用。
具鞘微鞘藻中含有多糖、蛋白、脂肪酸等多种成分,本申请中的沙漠藻护肤原料特指具鞘微鞘藻多糖,其提取方法包括:
(1)对具鞘微鞘藻经培养、采收后进行干燥、制粉得到具鞘微鞘藻粉末;本申请中的干燥优选为冷冻干燥,低温条件进行干燥可以最大限度的保留藻体内活性物质不被破坏。
(2)对具鞘微鞘藻粉末加入第一无水乙醇,具鞘微鞘藻粉末与第一无水乙醇的料液比为1:20-30,进行摇床震荡,随后过滤得到藻体。无水乙醇可以初步的对藻体脱色素和油脂。
(3)将藻体重新分散在水中,热碱法浸提,离心收集上清,重复提取三次,合并上清液后加入第二无水乙醇,低温醇沉,离心收集沉淀,干燥得到具鞘微鞘藻粗提取;
其中,热碱法浸提包括采用2wt%-3 wt%的NaOH调pH至9-11,65-75℃热水浸提3-4h;上清液与第二无水乙醇的体积比为1:3-5;
(4)将具鞘微鞘藻粗提取重新溶解于水,采用丙酮洗涤去色素,接着采用氯仿-正丁醇(氯仿和正丁醇的体积比为3-5:1)去蛋白,得到具鞘微鞘藻多糖。
将粗提物使用丙酮洗涤,进一步除去残留色素和油脂,重新溶解于水,得到粗提物水溶液;在粗提物水溶液中加入氯仿-正丁醇混合溶液进行充分振摇,将游离蛋白变性成为不溶性物质,离心后分在两相中间,变性的蛋白质一般在两相交界处产生一条白色的带,离心后得到沙漠藻护肤原料。采用此制备方法,可以有效去除具鞘微鞘藻中的蛋白,仅保留具鞘微鞘藻多糖,同时还可以显著减少提取物的色素和气味等,更适合应用于化妆品中,保证化妆品的质量。
本申请中将上述提取获得的具鞘微鞘藻多糖作为沙漠藻护肤原料,并对沙漠藻护肤原料进行了各种实验,经实验证明,本申请中的沙漠藻护肤原料具有皮肤舒缓的作用,具有强细胞舒缓能力,可以显著抑制脂多糖引起的巨噬细胞炎症因子(NO)的生成,降低炎症因子的释放,抑制外界刺激引起的皮肤血红素含量的增加,改善皮肤特别是干皮的症状,并且安全稳定,为其产业化应用奠定基础。因此,本申请中的皮肤舒缓剂为抑制巨噬细胞炎症因子释放和降低皮肤血红素含量的试剂。
为此,本申请提出了沙漠藻护肤原料在制备皮肤舒缓剂、巨噬细胞炎症因子释放抑制剂或降低皮肤血红素的试剂中的应用。
此外,本申请还可以将沙漠藻护肤原料添加到护肤品或化妆品中,提升护肤品或化妆品的皮肤舒缓的效果。
具体来说,本申请提出了沙漠藻护肤原料在制备化妆品或护肤品中的应用,尤其是,本申请还提供了一种护肤品,其组分按质量百分比计包括:保湿剂0.01-20%、增稠剂0.02-0.8%、PH调节剂0.01-1%、防腐剂0.01-0.15%、皮肤调理剂0.01-5%、增溶剂0.01-0.5%、芳香剂0.005-0.5%、皮肤舒缓剂0.01-20%和余量的水,其中,皮肤舒缓剂为沙漠藻护肤原料。
其中,保湿剂包括但不限于二丙二醇、甜菜碱、双丙甘醇、泛醇、1,3-丙二醇、丁二醇、1,2-戊二醇、1,2-己二醇、山梨糖醇、泛醇、甘油、PEG/PPG-17/6 共聚物、甘油聚丙烯酸酯、甘油聚醚-26、透明质酸钠中的一种或两种以上的组合。
增稠剂包括但不限于丙烯酸类/C10-30烷醇丙烯酸酯交联聚合物、羟乙基纤维素、黄原胶、丙烯酸羟乙酯/丙烯酰二甲基牛磺酸钠共聚物、卡波姆和丙烯酰二甲基牛磺酸铵/VP共聚物中的一种或两种以上的组合。
pH调节剂包括但不限于氨甲基丙醇、柠檬酸、柠檬酸钠、氢氧化钾、氢氧化钠、精氨酸等中的一种或两种以上的组合。
防腐剂包括但不限于苯氧乙醇、羟苯甲酯、苯甲酸及其盐、山梨酸及其盐、氯苯甘醚、羟苯丙酯中的一种或两种以上的组合。
皮肤调理剂包括但不限于尿囊素、石莼提取物、水解胶原、神经酰胺 2、β-葡聚糖、海藻糖、角鲨烷、褐藻提取物、石榴果提取物、对羟基苯乙酮、棕榈酰三肽-5、二肽二氨基丁酰苄基酰胺二乙酸盐、二裂酵母发酵产物溶胞产物、酵母菌发酵产物滤液、乳酸杆菌/大豆发酵产物提取物中的一种或两种以上的组合。通过添加皮肤调理剂,进一步为皮肤补充水分,并且可以减缓皮肤衰老。皮肤调理剂中有效成分,可以渗透到肌肤深处,被皮肤吸收,从而改善皮肤的状态。
增溶剂包括但不限于聚山梨醇酯-20、PEG-40 氢化蓖麻油、PPG-26-丁醇聚醚-26、PEG-100 硬脂酸酯和甘油硬脂酸酯的复合物、聚甘油-3 甲基葡糖二硬脂酸酯、聚丙烯酰胺和月桂醇聚醚-7和C13-14异链烷烃的复合物、甘油醇醚-25 PCA 异硬脂酸脂中的一种或两种以上的组合。
芳香剂包括但不限于香精。
皮肤舒缓剂为沙漠藻护肤原料,其的用量为0.01-20%,优选用量为0.5-20%,更进一步优选用量为0.5-15%。其中,随着用量的增加,其皮肤舒缓性能增加,当增加至20%后,其增速减缓,基于对成本及效果的考虑,所添加的皮肤舒缓剂沙漠藻护肤原料含量为0.5-15%为优选方案。
此外,本申请的护肤品中还可以加入螯合剂,螯合剂的加入量为0-1%,螯合剂可以是EDTA-2Na和/或EDTA-4Na等。
上述护肤品包括但不限于水剂、乳液、膏霜或凝露。本申请采用沙漠藻护肤原料为皮肤舒缓剂,能够有效缓解外界刺激引起的皮肤敏感。
以下结合实施例对本发明的特征和性能作进一步的详细描述。
实施例1:沙漠藻护肤原料的制备
(1)选取分离自沙漠干旱地区的具鞘微鞘藻进行培养,培养方法如下:
具鞘微鞘藻的BG11培养基组成为:1.5 g/L NaNO3,0.04 g/L K2HPO4,0.075 g/LMgSO4·7H2O,0.0284 g/L CaCl2,0.006 g/L 柠檬酸,0.006 g/L 柠檬酸铁铵,0.001 g/LEDTA-Na2,0.02 g/L Na2CO3,1mL/L A5 solution。本发明的具鞘微鞘藻接种于体积为50L塑料桶中过补充CO2将培养基pH控制在7.0-8.0之间,每天定时搅拌,培养周期为4周,周期内平均温度为25℃,光照条件为1000-2000Lux,时间设置为12小时光照/12小时黑暗。具鞘微鞘藻采收后进行冷冻干燥,制备成粉待用。
(2)沙漠藻护肤原料的提取方法为:
称取干重为20g的具鞘微鞘藻粉末,分别以1:25的料液比添加500 ml无水乙醇,摇床45℃,180 rpm过夜震荡以初步脱色素和油脂。次日过滤收集藻体并加入去离子水(1:20),用2.5%NaOH调pH至10,70℃热水浸提3h;
将上述混合物5000rpm离心收集上清。离心后沉淀重复提取三次,合并上清后加入4倍体积无水乙醇,4℃下进行醇沉12h,离心收集沉淀,冷冻干燥得到具鞘微鞘藻粗提取;
(3)对具鞘微鞘藻粗提取进行提纯操作:
将粗提物使用丙酮洗涤,直至洗脱液颜色不再变深为止,然后重新溶解于水,得到粗提物水溶液;
按照1:1的比例,在粗提物水溶液中加入氯仿-正丁醇混合液(4:1)进行充分振摇,5000rpm离心分离得到水相,重复上述步骤直至两项之间无明显白色的带出现,离心后得到沙漠藻护肤原料。经此操作,可以显著减少提取物的色素和气味,以此进行皮肤舒缓测试。
实施例2:细胞毒性测试
MTT储备液:将MTT用PBS配制成5mg/mL,过滤(0.22μm微孔滤膜),2℃-8℃避光保存。
MTT工作液:用无酚红培养基将MTT贮备液稀释成1mg/mL,使用时现配现用。
用于试验的小鼠单核巨噬细胞白血病细胞系RAW264.7株在检测前至少传代一次,在试验前一天接种于96孔板中,每孔接种量为100μL。细胞融合度达到50%-70%检测受试物的细胞毒性。弃掉96孔板中的培养基,根据表1中终浓度加入不同浓度的受试物溶液,同时设置空白对照组(NC),100μL/孔,每个浓度6个复孔进行加样,结束后,盖上细胞板盖,封边,置于二氧化碳培养箱中培养20h-48h。
培养结束后,弃去培养液,用PBS洗1至2次,加入MTT工作液,50μL/孔,继续置于二氧化碳培养箱培养2h-6h,弃去培养液,每孔加入150μL的DMSO,震荡5min-10min,用酶标仪测定570nm处吸光度值,采用630nm作为参考波长。根据结果计算细胞存活率,当样品在96孔板中对应浓度的细胞存活率≥90%(表1),且样品组的细胞与空白组细胞的形态无明显差异时,则说明样品在该浓度下无明显细胞毒性。
表1 细胞毒性测试样品浓度和对应浓度的细胞存活率
实施例3:巨噬细胞NO合成抑制测试
对沙漠藻护肤原料的细胞舒缓性能进行测试,所采用的测试方法为体外巨噬细胞一氧化氮(NO)释放抑制测定。
格里斯溶液:用纯水配制成1%浓度,室温避光保存,溶液应当澄清透明。
细菌脂多糖与巨噬细胞表面抗原识别受体相结合,诱导巨噬细胞释放炎症介质NO,过多的NO可以促进巨噬细胞释放IL-6、TNF-α等炎症因子,而这些炎症因子又可以促进细胞分泌更多的NO,形成恶性循环,加重炎症反应。通过测定给药后样品组的NO抑制率,评价样品对NO释放的抑制作用,从而评价样品是否具有舒缓功效。NO在体内或水溶液中极易氧化成NO2-,在酸性条件下,NO2-与重氮盐磺胺发生重氮反应,并生成重氮化合物,后者进一步与萘基乙烯基二胺发生耦合反应,该反应生成的产物浓度与NO浓度具有线性关系,在540nm处有最大吸收峰。用酶标仪测定540nm处光密度(OD)值,计算NO的相对含量。
在试验前一天接种于96孔板中,每孔接种量为100μL,细胞融合度达到80%-90%时,弃掉96孔板中的培养基,每孔加入50μL的受试物溶液,再加入50μL的LPS工作液,每孔总体积为100μL。同时还应设阳性对照组、模型对照组、空白对照组。模型对照组每孔加入50μL的试验培养基和50μL的LPS工作液,空白对照组每孔加入100μL的试验培养基。每组各6个复孔。加样完毕后将96孔板置二氧化碳培养箱中孵育培养24h±2h。孵育培养结束后,每孔收集50μL的细胞培养上清液放入一个新的96孔板中,每孔加入50μL的格里斯溶液,混匀后避光反应10min,用酶标仪在540nm处检测OD值。
NO抑制率% =(OD模型组−OD样品)/OD模型组×100%
本实施例还选取了不同来源的藻(小球藻和紫球藻培养方法参考具鞘微鞘藻、叉开网翼藻采自山东沿海、红毛藻和马尾藻采集自广东沿海),其提取方法均与沙漠藻护肤原料相同。
结合图1和图2及下表2,得到不同的受试物对巨噬细胞NO释放的抑制功效。
表2.具鞘微鞘藻抑制巨噬细胞炎症因子释放结果
从表2可以看出,并非所有的藻提取物均具有抑制巨噬细胞炎症因子释放的效果,尤其是其中的红毛藻提取物和具鞘微鞘藻蛋白还具有促进巨噬细胞炎症因子释放的效果,而本申请提供的沙漠藻护肤原料相较于其他来源的藻类可以显著抑制脂多糖引起的巨噬细胞NO生成,随着沙漠藻护肤原料浓度的升高,抑制效果增强。并且沙漠藻护肤原料与其他藻提取物相比,表现出优异的巨噬细胞NO释放抑制效果,将沙漠藻护肤原料作为皮肤舒缓剂具有广泛用途,其在制备化妆品中作为皮肤舒缓剂有巨大潜力。此外,本申请中具鞘微鞘藻粗提取即未去除色素和蛋白提取物,此时的NO抑制率相较于同等浓度的沙漠藻护肤原料显著降低,具鞘微鞘藻蛋白则无明显的NO释放抑制效果。
实施例4:护肤品
本实施例提供了一种护肤品,按下表3所示配制产品实施例1-4和产品对比例1。其中,在产品实施例1-4添加不同添加量的本发明所述沙漠藻护肤原料作为皮肤舒缓剂,在产品对比例1中不添加沙漠藻护肤原料。
表3.护肤品配方表
本实施例中上述配方的护肤品(舒缓霜)制备工艺为:
根据上表3中的配方中各组分的含量(质量百分比),并按照下述生产工艺步骤制备得到舒缓霜。生产工艺步骤如下:
1、将A相原料加入油相锅,搅拌并加热至80-85℃,使之充分溶解;
2、将B相加入乳化锅,搅拌并加热到80-85℃,使之充分溶解;
3、将油相锅内油相物质慢慢抽到乳化锅,搅拌、均质、真空乳化,保持乳化锅温度为80-85℃;
4、降温至42℃,加入C相和D相搅拌均匀;
5、冷却至37℃,出料,静置24小时;
6、检验合格后,分装、包装,再检验,成品入库。
注:工艺中的A、B、C、D相分别为
A相:肉豆蔻酸异丙酯、环聚二甲基硅氧烷、辛酸/癸酸甘油三酯、油醇芥酸酯、环己硅氧烷、聚甘油-3 甲基葡糖二硬脂酸酯、牛油果树果脂、聚二甲基硅氧烷、聚丙烯酰胺和月桂醇聚醚-7和C13-14异链烷烃的复合物、C12-15 醇苯甲酸酯、PEG-100 硬脂酸酯和甘油硬脂酸酯的复合物、生育酚乙酸酯、油橄榄油不皂化物、甘油聚丙烯酸酯、丙烯酰二甲基牛磺酸铵/VP 共聚物、丁羟甲苯、香精;
B相:水、甘油、1,3-丙二醇、泛醇、甜菜碱、氨甲基丙醇、尿囊素、卡波姆、氯化锰;
C相:聚乙二醇-90M、丁二醇;
D相:沙漠藻护肤原料、苯氧乙醇、1,2-己二醇、乳酸杆菌/大豆发酵产物提取物。
其中,甘油、泛醇、甜菜碱、甘油聚丙烯酸酯、1,3-丙二醇、1,2-己二醇、丁二醇为保湿剂;
肉豆蔻酸异丙酯、环聚二甲基硅氧烷、辛酸/癸酸甘油三酯、油醇芥酸酯、环己硅氧烷、牛油果树果脂、聚二甲基硅氧烷、C12-15 醇苯甲酸酯、油橄榄油不皂化物是油脂;
聚乙二醇-90M、丙烯酰二甲基牛磺酸铵/VP 共聚物、卡波姆是增稠剂;
沙漠藻护肤原料为皮肤舒缓剂;
聚甘油-3 甲基葡糖二硬脂酸酯、聚丙烯酰胺和月桂醇聚醚-7和C13-14异链烷烃的复合物、PEG-100 硬脂酸酯和甘油硬脂酸酯的复合物是乳化剂;
乳酸杆菌/大豆发酵产物提取物、尿囊素、氯化锰是皮肤调理剂;
丁羟甲苯、生育酚乙酸酯是抗氧化剂;
苯氧乙醇是防腐剂;
氨甲基丙醇是pH调节剂;香精是芳香剂。
PEG-100 硬脂酸酯和甘油硬脂酸酯的复合物,生产厂家,禾大公司,牌号:ARLACEL165;
聚丙烯酰胺和月桂醇聚醚-7和C13-14异链烷烃的复合物的生产厂家是赛比克公司,牌号为 Sepigel 305。
在本实施例中,对所得舒缓霜进行皮肤血红素含量测试。
皮肤血红素的测试原理:所有的敏感性肌肤都存在亚临床皮肤炎症,皮肤炎症导致血管通透性升高,血红素沉积。皮肤过薄易受外界刺激,出现接触性皮炎,红血丝等现象,也会加重皮肤潜在炎症反应。基于光谱吸收的原理(RGB),通过测定特定波长的光照在人体皮肤上后的反射量来确定皮肤中血红素的含量。仪器探头的发射器发出波长分别为568nm、660nm、和880nm三种波长的光照射在皮肤表面,接受器测得皮肤反射的光。由于发射光的量是一定的,因此就可以测出被皮肤吸收的光的量,测出皮肤血红素的含量。仪器的测量范围是0-999,测量数值越高,说明皮肤中血红素的含量越高。
皮肤血红素的测试方法:受试者人数为20人,试验选取产品实施例1-4的护肤品以及产品对比例1的护肤品作为测试样品,在受试者的前臂划分5个不同区域,涂抹量约为2mg/cm2。皮肤血红素含量的测试采用德国CK公司的色素检测仪进行测试,其中,测试探头MX 18由光源发射器和接收器组成,另有弹簧以保持检测时对皮肤的压力恒定。通过测量产品使用前后皮肤血红素的含量(相对于涂抹样品前的初始值)来评估该产品对受试区域皮肤的舒缓作用。
抗刺激模型:分别将产品实施例1-4的护肤品以及产品对比例1的护肤品作为测试样品与质量分数1%SDS混合后,在志愿者手前臂屈侧进行24h斑贴测试,对比不同样品组区域血红素的变化程度,敷贴24h后,移开斑试器。分别在撕斑贴后0.5h和第1、3、7天评价其舒缓功效。
舒缓刺激模型:志愿者手前臂屈侧用质量分数1%SDS进行24h斑贴诱导皮肤损伤产生炎症后,每天早晚分别使用不同样品组,记录皮肤血红素的变化程度,在撕斑贴后0.5h和第1/3/7天评价其舒缓功效。
结合附图3及下表4所示,其中表4为皮肤血红素含量,图3皮肤血红素含量比较图。
表4.抗刺激模型皮肤血红素含量
结合附图4及下表5所示,其中表5为皮肤血红素含量,图4皮肤血红素含量比较图。
表5.舒缓刺激模型皮肤血红素含量
降低率=[(0.5h的皮肤血红素含量-初始值的皮肤血红素含量)-(第7天的皮肤血红素含量-初始值的皮肤血红素含量)]/(0.5h的皮肤血红素含量-初始值的皮肤血红素含量)×100%。
由此可得,在护肤品中加入沙漠藻护肤原料可以降低皮肤血红素含量,起到舒缓皮肤作用。同时,随着沙漠藻护肤原料的用量增加,其效果增加。综合对比其成本及效果,沙漠藻护肤原料添加量在0.5-15%为较优实施方案。
以上所述仅为本发明的优选实施例而已,并不用于限制本发明,对于本领域的技术人员来说,本发明可以有各种更改和变化。凡在本发明的精神和原则之内,所作的任何修改、等同替换、改进等,均应包含在本发明的保护范围之内。
Claims (4)
1.沙漠藻护肤原料在制备皮肤舒缓剂中的应用,其特征在于,所述沙漠藻护肤原料为具鞘微鞘藻多糖,所述皮肤舒缓剂为抑制巨噬细胞炎症因子释放和降低皮肤血红素含量的试剂;
所述沙漠藻护肤原料的制备方法其包括:
对具鞘微鞘藻经培养、采收后进行干燥、制粉得到具鞘微鞘藻粉末;
对所述具鞘微鞘藻粉末加入第一无水乙醇,进行摇床震荡,随后过滤得到藻体;
将所述藻体重新分散在水中,热碱法浸提,离心收集上清,重复提取三次,合并上清液后加入第二无水乙醇,低温醇沉,离心收集沉淀,干燥得到具鞘微鞘藻粗提取;
将所述具鞘微鞘藻粗提取重新溶解于水,采用丙酮洗涤去色素,接着采用氯仿-正丁醇去蛋白,得到具鞘微鞘藻多糖,即为所述沙漠藻护肤原料;
所述具鞘微鞘藻粉末与所述第一无水乙醇的料液比为1:20-30,所述热碱法浸提包括采用2wt%-3 wt%的NaOH调pH至9-11,65-75℃热水浸提3-4h;所述上清液与所述第二无水乙醇的体积比为1:3-5;所述氯仿-正丁醇中氯仿和正丁醇的混合体积比为3-5:1。
2.一种护肤品,其特征在于,其组分按质量百分比计包括:保湿剂0.01-20%、增稠剂0.02-0.8%、PH调节剂0.01-1%、防腐剂0.01-0.15%、皮肤调理剂0.01-5%、增溶剂0.01-0.5%、芳香剂0.005-0.5%、皮肤舒缓剂0.01-20%和余量的水,其中,所述皮肤舒缓剂为如权利要求1所述的沙漠藻护肤原料在制备皮肤舒缓剂中的应用的所述沙漠藻护肤原料。
3.根据权利要求2所述的护肤品,其特征在于,所述护肤品包括水剂、乳液、膏霜或凝露。
4.一种舒缓霜,其特征在于,其组分包括A相、B相、C相和D相,按质量百分数计:
所述A相包括肉豆蔻酸异丙酯3.00%、环聚二甲基硅氧烷2.00%、辛酸/癸酸甘油三酯3.00%、油醇芥酸酯2.00%、环己硅氧烷1.00%、聚甘油-3 甲基葡糖二硬脂酸酯1.50%、牛油果树果脂2.00%、聚二甲基硅氧烷3.00%、聚丙烯酰胺和月桂醇聚醚-7和C13-14异链烷烃的复合物0.30%、C12-15 醇苯甲酸酯1.00%、PEG-100 硬脂酸酯和甘油硬脂酸酯的复合物1.00%、生育酚乙酸酯0.30%、油橄榄油不皂化物0.20%、甘油聚丙烯酸酯2.00%、丙烯酰二甲基牛磺酸铵/VP共聚物0.40%、丁羟甲苯0.05%、香精0.18%;
所述B相包括余量的水、甘油3.00%、1,3-丙二醇1.00%、泛醇1.00%、甜菜碱1.00%、氨甲基丙醇0.12%、尿囊素0.10%、卡波姆0.20%、氯化锰0.01%;
所述C相包括聚乙二醇-90M 2.00%、丁二醇3.00%;
所述D相包括如权利要求1所述的沙漠藻护肤原料在制备皮肤舒缓剂中的应用的所述沙漠藻护肤原料0.5%-20%、苯氧乙醇0.40%、1,2-己二醇0.40%、乳酸杆菌/大豆发酵产物提取物0.50%;
所述舒缓霜的制备方法包括:
将所述A相加入油相锅,搅拌并加热至80-85℃,使之充分溶解;
将所述B相加入乳化锅,搅拌并加热到80-85℃,使之充分溶解;
将所述油相锅内油相物质慢慢抽到所述乳化锅,搅拌、均质、真空乳化,保持乳化锅温度为80-85℃;
降温至42℃,加入所述C相和所述D相搅拌均匀;冷却至37℃,出料,静置24小时。
Priority Applications (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN202310029859.4A CN115737478B (zh) | 2023-01-09 | 2023-01-09 | 沙漠藻护肤原料在制备皮肤舒缓剂中的应用 |
PCT/CN2023/089415 WO2024148705A1 (zh) | 2023-01-09 | 2023-04-20 | 沙漠藻护肤原料在制备皮肤舒缓剂中的应用 |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN202310029859.4A CN115737478B (zh) | 2023-01-09 | 2023-01-09 | 沙漠藻护肤原料在制备皮肤舒缓剂中的应用 |
Publications (2)
Publication Number | Publication Date |
---|---|
CN115737478A CN115737478A (zh) | 2023-03-07 |
CN115737478B true CN115737478B (zh) | 2023-06-02 |
Family
ID=85348795
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN202310029859.4A Active CN115737478B (zh) | 2023-01-09 | 2023-01-09 | 沙漠藻护肤原料在制备皮肤舒缓剂中的应用 |
Country Status (2)
Country | Link |
---|---|
CN (1) | CN115737478B (zh) |
WO (1) | WO2024148705A1 (zh) |
Families Citing this family (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN115737478B (zh) * | 2023-01-09 | 2023-06-02 | 广州市科能化妆品科研有限公司 | 沙漠藻护肤原料在制备皮肤舒缓剂中的应用 |
Citations (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPH10265399A (ja) * | 1997-03-27 | 1998-10-06 | Agency Of Ind Science & Technol | 抗アレルギー剤および抗炎症剤 |
CN105949345A (zh) * | 2016-05-06 | 2016-09-21 | 信阳师范学院 | 一种具鞘微鞘藻胞内多糖的提取方法 |
CN111991276A (zh) * | 2020-09-28 | 2020-11-27 | 新疆金正生物科技有限公司 | 一种含沙漠藻提取物的保湿面霜及制备方法 |
CN114053169A (zh) * | 2020-07-30 | 2022-02-18 | 巴斯夫美容护理法国公司 | 水前寺蓝藻多糖的美容用途 |
CN114917178A (zh) * | 2022-05-27 | 2022-08-19 | 广州市科能化妆品科研有限公司 | 适用于沙漠干燥肌肤的舒缓修护组合物及其应用 |
CN115569106A (zh) * | 2022-09-09 | 2023-01-06 | 广州市科能化妆品科研有限公司 | 螺旋藻h11株系水提取物及其制备方法、应用和护肤品 |
Family Cites Families (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US9370537B2 (en) * | 2009-04-03 | 2016-06-21 | Cerule, Llc | Compositions and methods for reducing inflammation |
CN115737478B (zh) * | 2023-01-09 | 2023-06-02 | 广州市科能化妆品科研有限公司 | 沙漠藻护肤原料在制备皮肤舒缓剂中的应用 |
-
2023
- 2023-01-09 CN CN202310029859.4A patent/CN115737478B/zh active Active
- 2023-04-20 WO PCT/CN2023/089415 patent/WO2024148705A1/zh unknown
Patent Citations (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPH10265399A (ja) * | 1997-03-27 | 1998-10-06 | Agency Of Ind Science & Technol | 抗アレルギー剤および抗炎症剤 |
CN105949345A (zh) * | 2016-05-06 | 2016-09-21 | 信阳师范学院 | 一种具鞘微鞘藻胞内多糖的提取方法 |
CN114053169A (zh) * | 2020-07-30 | 2022-02-18 | 巴斯夫美容护理法国公司 | 水前寺蓝藻多糖的美容用途 |
CN111991276A (zh) * | 2020-09-28 | 2020-11-27 | 新疆金正生物科技有限公司 | 一种含沙漠藻提取物的保湿面霜及制备方法 |
CN114917178A (zh) * | 2022-05-27 | 2022-08-19 | 广州市科能化妆品科研有限公司 | 适用于沙漠干燥肌肤的舒缓修护组合物及其应用 |
CN115569106A (zh) * | 2022-09-09 | 2023-01-06 | 广州市科能化妆品科研有限公司 | 螺旋藻h11株系水提取物及其制备方法、应用和护肤品 |
Also Published As
Publication number | Publication date |
---|---|
WO2024148705A1 (zh) | 2024-07-18 |
CN115737478A (zh) | 2023-03-07 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
JP2009501160A (ja) | ヤエナリ乳酸菌培養物及びその製造方法、並びに該培養物を含有する化粧料組成物 | |
KR101566320B1 (ko) | 봉선화, 영실, 마카, 비파나무 잎 및 얌빈 뿌리 복합발효추출물을 포함하는 피부 재생, 진정 및 자극완화용 화장료조성물 | |
JP3432940B2 (ja) | 皮膚外用剤 | |
CN115737478B (zh) | 沙漠藻护肤原料在制备皮肤舒缓剂中的应用 | |
CN112842953A (zh) | 酵母菌发酵的桦树汁及其在保湿化妆品组合物中的应用 | |
KR101727788B1 (ko) | 글루쿠론산을 다량 함유하는 지충이 분해물 제조 방법 및 이를 함유하는 항노화 기능성 화장료 조성물 | |
KR101435874B1 (ko) | 강황 잎 추출물을 함유하는 화장료 조성물 및 그 제조방법 | |
JP2023171950A (ja) | 抗老化剤、抗酸化剤、抗炎症剤、及び美白剤、並びに、化粧料 | |
KR101645476B1 (ko) | 흑효모 발효를 통해 비타민 c 함량이 증가된 산자나무 발효 추출물을 함유하는 화장료 조성물 | |
KR20120054298A (ko) | 발효 콩잎 추출물을 유효성분으로 함유하는 피부 외용제 조성물 | |
KR101810410B1 (ko) | 버섯 균사체 및 청호밀 태좌의 혼합 배양 추출물의 제조방법 및 이를 함유하는 화장료 조성물 | |
CN115569106B (zh) | 螺旋藻h11株系水提取物及其制备方法、应用和护肤品 | |
KR20170011035A (ko) | 알로에베라 잎 복합 추출물을 함유하는 열노화 방지용 화장료 조성물 | |
KR101326102B1 (ko) | 홍국 발효 추출물을 포함하는 화장료 조성물 | |
CN112386562B (zh) | 一种植物发酵方法在护肤品中的应用及其组合物 | |
KR101843976B1 (ko) | 흑효모 발효 발아녹두 추출물을 유효성분으로 함유하는 화장료 조성물 | |
KR20200054590A (ko) | 미강 발효 고형분을 유효성분으로 함유한 피부 장벽 강화용 화장료 조성물 | |
KR20170005534A (ko) | 천연배지를 이용한 잔나비걸상버섯 균사체 배양액을 함유하는 화장료 조성물 | |
KR20180082058A (ko) | 천연 복합 추출물을 유효성분으로 포함하는 각질 박리용 화장료 조성물 | |
KR101951646B1 (ko) | 스피룰리나 마리노박터 발효 추출물을 유효성분으로 포함하는 항산화 및 주름개선용 화장료 조성물 | |
KR20120007170A (ko) | 닥나무 또는 그 추출물의 발효방법, 그 발효 추출물 및 이를 포함하는 화장료 조성물 | |
KR20150136290A (ko) | 봉독 추출물, 버드나무 껍질 추출물 및 쌀 발효 추출물을 함유하는 노화방지용 화장료 조성물 | |
CN113181088A (zh) | 胶原酶抑制剂及其制备方法和包含该胶原酶抑制剂的透肌水 | |
KR101855210B1 (ko) | 흑효모 발효 가지씨 초음파 추출물을 함유하는 화장료 조성물 | |
KR20210025870A (ko) | 감태, 톳, 개청각, 우뭇가사리, 제주진득찰 및 랍도시아루베스켄스의 혼합 추출물을 유효성분으로 함유하는 피부 보습용 화장료 조성물 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PB01 | Publication | ||
PB01 | Publication | ||
SE01 | Entry into force of request for substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
GR01 | Patent grant | ||
GR01 | Patent grant |